Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
DAFTAR PUSTAKA Aguilar, F.M., Aguirre, C.M.L., Rocha, J.C.M., Chavez, J.A., Trevino, V., Padilla, C.R., Perez, D.R. 2013. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia-Pac J Clin Oncol 9: 53–59. American Type Culture Collection (ATCC). 2014. http://www.atcc.org/products/all/HTB-22.aspx#characteristics.[15 April 2014]. Aryandono, T. 2006. Faktor Prognosis Kanker Payudara Operable di Yogyakarta. Disertasi. Universitas Gadjah Mada. Yogyakarta. Badan Penelitian dan Pengembangan Kesehatan (Litbangkes) Kementrian Kesehatan RI. 2013. Riset Kesehatan Dasar 2013. Kementrian Kesehatan RI. Jakarta. Ballantyne, K.N., van Oorschot, R.A.H, Mitchell, R.J. 2008. Locked nucleic acids in PCR primers increase sensitivity and performance. Genomics 91: 301–305. Baselga, J. 2011. Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer. Oncologist 16: 12–19. Bray, J., Sludden, J., Griffin, M.J., Cole, M., Verrill, M., Jamieson, D., Boddy. 2010. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British J Can 102: 1003 – 1009. Castaneda, C.A., Cortes-Funes, H., Gomez, H.L., Ciruelos, E.M. 2010. The phosphatidyl inositol 3-kinase/akt signaling pathway in breast cancer. Cancer Metastasis Rev 29:751-759. Chan, J.A., Krichevsky, A.M., Kosik, K.S. 2005. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65: 6029-6033. Chekhun, V.F., Kulik, G.I., Yurchenko, O.V., Tryndyak, V.P., Todor, I.N., Luniv, L.S., Tregubova, N.A., Pryzimirska, T.V., Montgomery, B., Rusetskaya, N.V., Pogribny, I.P. 2006. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Can Let 231: 87–93. De Graffenried, L.A., Fulcher, L., Friedrichs, W.E., Gru¨nwald, V., Ray, R.B., Hidalgo, M. 2004. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15: 1510–1516. 61 62 Di Cristofano, A., Pandolfi, P.P. 2000. The multiple roles of PTEN in tumor suppression. Cell 100: 387–390. Fix, L.N., Shah, M., Efferth, T., Farwell, M.A., Zhang, B. 2010. MicroRNA Expression Profile of MCF-7 Human Breast Cancer Cells and the Effect of Green Tea Polyphenon-60. Cancer Genom Proteom 7: 261-278. Frankel, L.B., Christoffersen, N.R., Jacobsen, A., Lindow, M., Krogh, A., Lund, A.H. 2008. Programmed Cell Death 4 (PDCD4) Is an Important Functional Target of the MicroRNA miR-21 in Breast Cancer Cells. J Biol Chem 283:1026-1033. Globocan-IARC. 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, World Health Organization. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. [12 Januari 2015]. Gonzalez-Angulo, A.M., Ferrer-Lozano, J., Stemke-Hale., K., Sahin, A., Liu, S., Barrera, J.A., Burgues, O., Lluch, A.M., Chen, H., Hortobagyi, G.N., Mills, G.B., MericBernstam, F. 2011. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Mol Cancer Ther 10 (6): 1093–1101. Gottesman, M.M., Fojo, T., Bates, S.E. 2002. Multidrug Resistance: Role of ATPDependent Transporters. Nature 2: 48-58. Glodek, C. 1990. A History of the Michigan Cancer Foundation, the Beginnings & Growth of Detroit's Anticancer Movement. Michigan Cancer Foundation.International Agency for Research on Cancer (IARC). http://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf. [17 April 2014]. Hunt, K.K., Newman, L.A., Copeland, E.M., Bland, K.I. 2010. Breast dalam Schwart’s Principle of Surgery. Mc Graw Hill. New York. Hunz, M., Jetter, A., Warm, M., Pantke, E., Tuscher, M., Hempel, G., Jaehde, U., Untch, M., Kurbacher, C., Fuhr, U. 2007. Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther 81: 659–668. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D. 2011. Global cancer statistics. CA Cancer J Clin 61: 69-90. Juliette, J.A. and Lin, S.X. 2012. Comparison of Functional Proteomic Analyses of Human Breast Cancer Cell Lines T47D and MCF7. PlosONE 7(2): e31532.doi:10.1371/journal.pone.0031532. 63 Katzung, G.B., Masters, B.S., Trevor, J.A. 2009. Basic and Clinical Pharmacology. McGraw Hill. USA. Pp.1091-1116. Kementerian Kesehatan RI. 2010. Profil Kesehatan Indonesia Tahun 2009. Kementrian Kesehatan RI. Jakarta. Leslie, N.R., Batty, I.H., Maccario, H., Davidson, L., Downes, C.P. 2008. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 27: 5464–5476. Li, L.Q., Li, X.L., Wang, L., Du, W.J., Guo, R., Liang, H.H., Liu, X., Liang, D.S., Lu, Y.J., Shan, H.L., Jiang, H.C. 2012. Matrine Inhibits Breast Cancer Growth Via miR21/PTEN/Akt Pathway in MCF-7 Cells. Cell Physiol Biochem 30: 631-641. Livak, K.J. and Schmittgen, T.D. 2001. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-∆∆CT Method. Methods 25: 402-408. Lou, Y.H., Yang, Q.S.,Wang, F., Cui, Z., Huang, Y. 2010. MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Intl J Mol Med 26: 819-827. Lu, Z., Liu, M., Stribinskis, V., Klinge, C.M., Ramos, K.S., Colburn, N.H., Li, Y. 2008. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27: 4373–4379. Lunn, M.L., Mouritzen, P., Faber, K., Jacobsen, N. 2008. MicroRNA quantitation from a single cell by PCR using SYBR®Green detection and LNA-based primers. Nature methods: 3-4. Lukyanova, N.Y., Rusetskya, N.V., Tregubova, N.A., Chekhun, V.F. 2009. Molecular Profile and Cell Cycle in MCF-7 Cells Resistant to Cisplatin and Doxorubicin. Exp Oncol 2: 87–91 Mc Cubrey, J.A. , Steelmana, L.S., Abramsa, S.L., Leea, J.T., Changa, F., Bertranda, F.E., Navolanica, P.M., Terrianb, D.M., Franklina, R.A., D’Assorod, A., Salisburyd, J.L., Mazzarinoe, M.C., Stivalae, F., Libra, M. 2006. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT Pathways in Malignant Transformation and Drug Resistance. Advan Enzyme Regul 46: 249–279. Meng, F., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T., Patel, T. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658. 64 Miller, T.W., Rexer, B.N., Garrett, J.T., Arteaga, C.L. 2011. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13: 224. Molinari, F. and Frattini, M. 2014. Functions and regulation of the PTEN gene in colorectal cancer. Fonc 3: 1-8. Ollson, M. and Zhivotovsky. 2011. Caspases and Cancer. Cell Death Diff. 18:1441-1449. Papagiannakopoulos, T., Shapiro, A., Kosik, K.S. 2008. MicroRNA-21 Targets a Network of Key Tumor-Suppressive. Pathways in Glioblastoma Cells. Cancer Res 68: 81648172. Pelengaris, S. and Khan, M. 2006. The Molecular Biology of Cancer. Blackwell Pub. USA. Pp 1-478. Phin, S., Moore, M.W., Cotter, P.D. 2013. Genomic rearrangements of PTEN in prostate cancer. Fonc 3: 1-9. Pritchard, J.E., Dillon, P.M., Conaway, M.R., Silva, C.M., Parsons, S.J. 2012. A Mechanistic Study of the Effect of Doxorubicin/Adriamycin on the Estrogen Response in a Breast Cancer Model. Oncology 83(6): 305–320. Qi, L., Bart, J., Tan, L.P., Platteel, I., Sluis, T., Huitema, S., Harms, G., Fu, L., Hollema, H., Berg, A. 2009. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9: 163-171. Riaz, M., van Jaarsveld, M.T.M., Hollestelle, A., Prager-van der Smissen, W.J.C., Heine, A.A.J., Boersma, A.W.M., Liu, J., Helmijr, J., Ozturk, B., Smid, M., Wiemer, E.A., Foekens, J.A., Martens, W.M. 2013. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res 15: R33-R50. Rusetskya, N.V., Lukyanova, N.Y., Chekhun, V. F. 2009. Molecular Profile and Cell Cycle in MCF-7 and MCF-7 /DOX Cells Exposed to Conventional and Liposomal Form of Doxorubicin. Exp Oncol 31: 140–143. Schwarzenbach, H., Nishida, N., Calin, G.A., Pantel, K. 2014. Clinical relevance of circulating cell-free microRNAs in cancer. Nature Clin Oncol 11: 145-156. Shi, Y., Moon, M., Dawood, S., McManus, B. & Liu, P.P. 2011. Mechanisms and management of doxorubicin cardiotoxicity. Herz 36(4): 296-305. 65 Si, M.L., Zhu, S., Wu, H., Lu, Z., Wu, F., Mo, Y.Y. 2007. miR-21-mediated tumor growth. Oncogene 26: 2799-2803. Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., Haga, N. 2002. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94 (1): 15-21. Vazquez, F. and Sellers, W.R. 2000. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470: M21-M35. Volinia, S., Galasso, M., Costinean, S., Tagliavini, L., Gamberoni, G., Drusco, A. 2010. Reprogramming of miRNA networks in cancer and leukemia. Gen Res 20: 589-599. Wang, Z.X., Lu, B.B., Wang, H., Cheng, Z.X., Yin, Y.M. 2011. MicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN. Archive Med Res 42: 281-290. Weber, F.G. 2007. Molecular Mechanisms of Cancer. Springer. USA. Weng, L.P., Smith, W.M., Dahia, P.L., Ziebold, U., Gil, E., Lees, J.A., Eng, C. 1999. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 59:5808-5814. Wind, N.S. and Holen, I. 2011.Multidrug Resistance in Breast Cancer:From In Vitro Models to Clinical Studies. Intl J Breast Cancer. doi:10.4061/2011/967419. Yan, L.X., Huang, X.F., Shao, Q., Huang, M.Y., Deng, L., Wu, Q.L., Zeng, Y.X. 2008. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348–2360. Yan, L.X., Wu, Q.N, Zhang, Y., Li, Y.Y., Liao, D.Z., Hou, J.H., Fu, J., Zeng, M.S. 2011. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 13: R2-R16. Zampieri L, P Bianchi, P Ruff, P Arbuthnot. 2002. Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. Anticancer Res 22(4): 2253-2259. Zhang, H.Y., Liang, F., Jia, Z.L., Song, S.T., Jiang, Z.F. 2013. PTEN mutation, methylation and expression in breast cancer patients. Onc let 6: 161-168. Zhu, S., Si, M.L., Wu, H., Mo, Y.Y. 2007. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336.